Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215 28 September 2021 | Press release
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X 27 July 2021 | Press release
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications 17 June 2021 | Press release
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies 7 April 2021 | Press release
Artios Pharma to Attend Upcoming Conferences in February and March 2021 18 February 2021 | Press release
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients 11 February 2021 | Press release
Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer 12 January 2021 | Press release
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology 3 December 2020 | Press release
Artios Pharma Strengthens Clinical Development Team with Senior Appointments 10 February 2020 | Press release
Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor 6 November 2019 | Press release